TradingKey

关于 Vanda Pharmaceuticals Inc 公司

Vanda Pharmaceuticals Inc. 是一家生物制药公司，专注于开发和商业化疗法，以满足大量未满足的医疗需求并改善患者的生活。该公司的商业产品组合由三种产品组成：HETLIOZ，用于治疗非 24 小时睡眠-觉醒障碍 (Non-24) 和用于治疗史密斯-马吉尼斯综合征 (SMS) 的夜间睡眠障碍；Fanapt (伊潘立酮)，用于治疗 I 型双相情感障碍和用于治疗精神分裂症的长效注射剂 (LAI)；PONVORY (ponesimod)，用于治疗炎症/自身免疫性疾病，包括溃疡性结肠炎、牛皮癣、克罗恩病、特应性皮炎、嗜酸性食管炎和斑秃。该公司还正在开发一系列药物，包括 Tradipitant (VLY-686)、VHX-896、VSJ-110、VPO-227、VTR-297、VQW-765、VCA-894A 和 Type 2S (CMT2S)。

公司简介

公司代码VNDA

公司名称Vanda Pharmaceuticals Inc

上市日期Apr 12, 2006

CEODr. Mihael Hristos Polymeropoulos, M.D.

员工数量368

证券类型Ordinary Share

年结日Apr 12

公司地址Suite 300E

城市WASHINGTON

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编20037

电话12027343400

网址https://www.vandapharma.com/

公司代码VNDA

上市日期Apr 12, 2006

CEODr. Mihael Hristos Polymeropoulos, M.D.

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.33M

+1.31%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

Dr. Stephen Ray Mitchell, M.D.

Independent Director

97.08K

+116.43%

Mr. Timothy I. Williams

Senior Vice President, General Counsel, Secretary

--

Ms. Phaedra S. Chrousos

Independent Director

--

Mr. Joakim (Kim) Wijkstrom

Senior Vice President, Chief Marketing Officer

--

名称

名称/职务

职务

持股

持股变动

Dr. Mihael Hristos Polymeropoulos, M.D.

Chairman of the Board, President, Chief Executive Officer

2.33M

+1.31%

Mr. Gunther Birznieks

Senior Vice President - Business Development

411.63K

+73.26%

Mr. Kevin Patrick Moran

Chief Financial Officer, Senior Vice President, Treasurer

329.46K

+118.08%

Mr. Richard W. Dugan

Lead Independent Director

177.45K

+50.09%

Dr. Tage Honore, Ph.D.

Independent Director

123.47K

+92.19%

Ms. Anne Sempowski Ward

Independent Director

119.07K

+98.97%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Fanapt

23.55M

47.05%

Hetlioz

20.87M

41.71%

PONVORY

5.62M

11.24%

暂无数据

业务

地区

业务USD

名称

营收

占比

Fanapt

23.55M

47.05%

Hetlioz

20.87M

41.71%

PONVORY

5.62M

11.24%

股东统计

更新时间: 5月16日周五

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.18%

Renaissance Technologies LLC

6.04%

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.30%

Other

68.29%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.18%

Renaissance Technologies LLC

6.04%

The Vanguard Group, Inc.

5.92%

Millennium Management LLC

5.28%

Dimensional Fund Advisors, L.P.

4.30%

Other

68.29%

股东类型

持股股东

占比

Investment Advisor

28.86%

Investment Advisor/Hedge Fund

26.88%

Hedge Fund

19.28%

Individual Investor

7.20%

Research Firm

2.93%

Pension Fund

0.44%

Bank and Trust

0.20%

Sovereign Wealth Fund

0.20%

Venture Capital

0.12%

Other

13.90%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

415

50.78M

86.17%

-11.31M

2025Q1

426

48.51M

82.37%

-12.27M

2024Q4

444

46.48M

79.71%

-15.23M

2024Q3

446

47.42M

81.36%

-14.93M

2024Q2

445

46.99M

80.73%

-18.42M

2024Q1

434

53.50M

92.97%

-11.41M

2023Q4

445

55.38M

96.27%

-9.21M

2023Q3

446

56.79M

98.75%

-12.15M

2023Q2

434

60.42M

105.19%

-10.16M

2023Q1

437

62.04M

109.27%

-2.85M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

6.02M

10.21%

+16.86K

+0.28%

Mar 31, 2025

Renaissance Technologies LLC

3.57M

6.05%

-287.37K

-7.46%

Mar 31, 2025

The Vanguard Group, Inc.

3.50M

5.93%

-11.00K

-0.31%

Mar 31, 2025

Millennium Management LLC

3.12M

5.29%

+980.75K

+45.84%

Jun 27, 2025

Dimensional Fund Advisors, L.P.

2.54M

4.31%

+51.16K

+2.06%

Mar 31, 2025

Tang Capital Management, LLC

2.35M

3.99%

--

Mar 31, 2025

Polymeropoulos (Mihael Hristos)

2.33M

3.95%

+30.00K

+1.31%

May 21, 2025

BlackRock Financial Management, Inc.

2.15M

3.64%

+14.97K

+0.70%

Mar 31, 2025

Acadian Asset Management LLC

1.89M

3.2%

-12.95K

-0.68%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.61M

2.74%

+163.33K

+11.26%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

0.64%

Invesco NASDAQ Future Gen 200 ETF

0.49%

ALPS Medical Breakthroughs ETF

0.19%

SPDR SSGA US Small Cap Low Volatility Index ETF

0.13%

Fidelity Small-Mid Multifactor ETF

0.09%

Federated Hermes MDT Small Cap Core ETF

0.08%

iShares Micro-Cap ETF

0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.04%

Franklin US Small Cap Multifactor Index ETF

0.04%

Fidelity Enhanced Small Cap ETF

0.03%

iShares Neuroscience and Healthcare ETF

占比0.64%

Invesco NASDAQ Future Gen 200 ETF

占比0.49%

ALPS Medical Breakthroughs ETF

占比0.19%

SPDR SSGA US Small Cap Low Volatility Index ETF

占比0.13%

Fidelity Small-Mid Multifactor ETF

占比0.09%

Federated Hermes MDT Small Cap Core ETF

占比0.08%

iShares Micro-Cap ETF

占比0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.04%

Franklin US Small Cap Multifactor Index ETF

占比0.04%

Fidelity Enhanced Small Cap ETF

占比0.03%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Vanda Pharmaceuticals Inc

4.185USD

Vanda Pharmaceuticals Inc

4.185

概览

公司

财务